Kenvue Inc. (NYSE:KVUE) Shares Purchased by Larson Financial Group LLC

Larson Financial Group LLC boosted its stake in Kenvue Inc. (NYSE:KVUE) by 81.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 18,830 shares of the company’s stock after purchasing an additional 8,473 shares during the period. Larson Financial Group LLC’s holdings in Kenvue were worth $436,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Huntington National Bank grew its stake in shares of Kenvue by 26.5% in the third quarter. Huntington National Bank now owns 4,161 shares of the company’s stock valued at $96,000 after buying an additional 871 shares in the last quarter. ING Groep NV grew its position in Kenvue by 23.6% in the 3rd quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock valued at $82,727,000 after acquiring an additional 681,954 shares in the last quarter. Lorne Steinberg Wealth Management Inc. increased its stake in Kenvue by 59.0% during the second quarter. Lorne Steinberg Wealth Management Inc. now owns 154,690 shares of the company’s stock worth $2,812,000 after purchasing an additional 57,375 shares during the period. Kennon Green & Company LLC lifted its position in shares of Kenvue by 140.7% during the second quarter. Kennon Green & Company LLC now owns 159,106 shares of the company’s stock worth $2,893,000 after purchasing an additional 93,008 shares in the last quarter. Finally, Czech National Bank boosted its stake in shares of Kenvue by 20.3% in the second quarter. Czech National Bank now owns 364,886 shares of the company’s stock valued at $6,634,000 after purchasing an additional 61,635 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 0.5 %

Shares of Kenvue stock opened at $24.12 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a fifty day simple moving average of $22.87 and a 200-day simple moving average of $20.92. The stock has a market cap of $46.24 billion, a price-to-earnings ratio of 43.85, a PEG ratio of 2.19 and a beta of 1.36. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter in the prior year, the firm posted $0.31 earnings per share. Kenvue’s revenue for the quarter was down .4% on a year-over-year basis. On average, equities analysts forecast that Kenvue Inc. will post 1.07 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.40%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Bank of America increased their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft lifted their target price on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Piper Sandler upped their price target on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a report on Monday, September 23rd. Royal Bank of Canada cut Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective for the company. in a research note on Tuesday, September 24th. Finally, UBS Group upped their target price on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.